SBP-2L Activators
SBP-2L activators are a class of chemical compounds that interact with the sterol regulatory element-binding protein (SREBP) cleavage-activating protein (SCAP), which is involved in the regulation of lipid homeostasis. Sterol regulatory element-binding proteins are transcription factors that are crucial for the regulation of genes involved in the synthesis and uptake of cholesterol, fatty acids, triglycerides, and phospholipids. In a typical state, SREBPs are bound to SCAP and sequestered in the endoplasmic reticulum (ER) membrane. When sterol levels in the cell are low, SCAP changes conformation, escorting SREBPs to the Golgi apparatus, where they are cleaved by two proteases, S1P and S2P. This process releases the active form of SREBPs into the cytoplasm, which then translocates to the nucleus to activate gene expression.
SBP-2L activators specifically target the interaction between SREBPs and SCAP, influencing the conformational state of SCAP and thereby affecting the regulatory mechanism of lipid metabolism. By modulating this interaction, SBP-2L activators can alter the rate at which SREBPs are escorted to the Golgi and subsequently cleaved, which in turn can change the levels of transcriptionally active SREBPs in the nucleus. This modulation is significant because it directly impacts the expression of genes under the control of SREBPs. The precise chemical structure and mechanism of action of these activators can vary, but they all share the common goal of influencing the SREBP-SCAP pathway. By doing so, SBP-2L activators are able to play a role in the regulation of lipid levels within cells, engaging in the complex interplay of lipid synthesis, uptake, and overall cellular lipid balance.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin directly stimulates adenylyl cyclase, leading to an increase in the intracellular levels of cAMP. Elevated cAMP activates PKA (protein kinase A), which can phosphorylate various target proteins, potentially enhancing the activity of SBP-2L by phosphorylation, assuming SBP-2L has phosphorylation sites for PKA. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which is involved in controlling the function of proteins through phosphorylation. By activating PKC, PMA could enhance the phosphorylation state of SBP-2L if it is a PKC substrate, thus increasing its activity. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $96.00 $264.00 | 2 | |
Ionomycin acts as a calcium ionophore, raising intracellular calcium levels. This can lead to the activation of calcium-dependent protein kinases, which may enhance the activity of SBP-2L if it is regulated by calcium-dependent phosphorylation. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a potent antioxidant that can inhibit certain protein kinases. By inhibiting competitive kinases, EGCG may relieve negative regulation on signaling pathways that control the activity of SBP-2L, thus indirectly enhancing its function. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
8-Bromo-cAMP is a cell-permeable cAMP analog that activates PKA. By activating PKA, it can enhance the phosphorylation and activation of SBP-2L if SBP-2L is regulated by PKA-mediated phosphorylation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that alters the PI3K/AKT pathway, leading to changes in downstream signaling. By inhibiting PI3K, LY294002 might indirectly increase the activity of SBP-2L if SBP-2L is part of a pathway that is negatively regulated by PI3K/AKT signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream of ERK in the MAPK pathway. By inhibiting MEK, U0126 can affect downstream signaling that may include the activation of SBP-2L if SBP-2L is part of the MAPK-regulated processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a specific inhibitor of MEK, which could enhance the activity of SBP-2L by inhibiting pathways that negatively regulate SBP-2L, assuming SBP-2L functions are modulated within the MAPK pathway. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate is involved in intracellular signaling and can activate sphingosine kinase. This signaling lipid could enhance the activity of SBP-2L through sphingolipid signaling pathways if SBP-2L is modulated by such pathways. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor that leads to an increase in cytosolic calcium levels. Elevated calcium can indirectly enhance the activity of SBP-2L through activation of calcium-dependent signaling pathways. | ||||||